Skip to main content

Table 2 Characteristics of study participants from ROS/MAP (N = 2079) and ADNI1/GO/2 (N = 1419) after QC of genetic data

From: Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction

ROS/MAP

AD (n = 564)

Non-ADa (n = 1515)

Diff (P)b

 Sex (F/M)

388 F, 176 M

1060 F, 455 M

0.63

 Age at death, years (SD)

90.92 (5.88)

88.10 (6.73)

< 0.0001

 APOE ε4 status (−/+)

− 378, + 186 (0.33)

− 1226, + 289 (0.19)

< 0.0001

ADNI

AD (n = 555)

Non-AD (n = 864)

Diff (P)b

 Sex (F/M)

231 F, 324 M

372 F, 492 M

0.62

 Age at AD, years (SD)

74.78 (8.11)

77.49 (7.33)

< 0.0001

 APOE ε4 status (−/+)

−201, + 354 (0.64)

− 568, + 296 (0.34)

< 0.0001

  1. ROS/MAP, The Religious Orders Study/the Rush Memory and Aging Project; ADNI, Alzheimer’s Disease Neuroimaging Initiative; AD, Alzheimer’s disease; Diff, the statistical difference between AD and non-AD; F, female; M, male; SD, standard deviation; Age at AD, age when AD developed for AD patients or age at last valid record for non-AD subjects; APOE ε4 status (−/+), presence of the ε4 allele
  2. aNon-AD in ROS/MAP includes 713 individuals with missing AD status
  3. bP values are calculated by Fisher’s exact tests (for sex and APOE ε4 status) or two-sample t tests (for age at death, age at AD)
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193